S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Twitter executive responsible for content safety resigns after Elon Musk criticism
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Twitter executive responsible for content safety resigns after Elon Musk criticism
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Twitter executive responsible for content safety resigns after Elon Musk criticism
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Twitter executive responsible for content safety resigns after Elon Musk criticism
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
NASDAQ:OTIC

Otonomy (OTIC) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.0085
▼
$0.0085
50-Day Range
$0.01
▼
$0.12
52-Week Range
$0.01
▼
$2.54
Volume
N/A
Average Volume
937,525 shs
Market Capitalization
$582,479.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$0.50
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

OTIC stock logo

About Otonomy (NASDAQ:OTIC) Stock

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

OTIC Stock News Headlines

May 10, 2023 | americanbankingnews.com
Otonomy (NASDAQ:OTIC) Receives New Coverage from Analysts at StockNews.com
April 29, 2023 | americanbankingnews.com
Otonomy (NASDAQ:OTIC) vs. Mainz Biomed (NASDAQ:MYNZ) Head to Head Analysis
June 3, 2023 | Behind the Markets (Ad)
"How war impacts the stock market"
Russia's invasion of Ukraine has already sent the stock market down 10%. But that's just the opening act for the new Russia-China Alliance. There's a major event involving China that's heating up... and it could boil over as soon as April 16th, 2023. Click Here to Learn How to Protect Your Retirement
April 24, 2023 | americanbankingnews.com
Otonomy (NASDAQ:OTIC) Now Covered by Analysts at StockNews.com
April 17, 2023 | americanbankingnews.com
Otonomy (NASDAQ:OTIC) Now Covered by StockNews.com
January 23, 2023 | finance.yahoo.com
Otonomy, Inc. (OTIC) Stock Historical Prices & Data - Yahoo Finance
December 21, 2022 | finanznachrichten.de
Otonomy, Inc.: Otonomy Provides Corporate Update
December 19, 2022 | finance.yahoo.com
Otonomy Provides Corporate Update
June 3, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
November 30, 2022 | investorplace.com
5 Investors Betting Big on Otonomy (OTIC) Stock
November 29, 2022 | investorplace.com
Why Is Otonomy (OTIC) Stock Up 97% Today?
November 10, 2022 | finance.yahoo.com
Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 6, 2022 | reuters.com
OTIC.OQ - Otonomy Inc | Stock Price & Latest News | Reuters
October 14, 2022 | marketscreener.com
OTONOMY, INC. : Results of Operations and Financial Condition (form 8-K) - Marketscreener.com
October 13, 2022 | investing.com
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.83% By Investing.com - Investing.com
October 13, 2022 | finance.yahoo.com
LianBio To Shut BridgeBio-Partnered Bile Duct Cancer Drug Trial - Yahoo Finance
October 13, 2022 | streetinsider.com
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.83% - StreetInsider.com
October 13, 2022 | benzinga.com
Otonomy shares are trading lower after the company reported higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baseline. - Otonomy (NASDAQ:OTIC) - Benzinga
October 13, 2022 | marketscreener.com
Otonomy Sees No Clinically Meaningful Improvement With Higher Doses of OTO-413 in Patients With Hearing Loss -- Shares Nosedive - Marketscreener.com
October 13, 2022 | benzinga.com
Why Laser Photonics Shares Are Trading Higher By Around 44%, Here Are 50 Stocks Moving In Thursday’s Mid- - Benzinga
October 13, 2022 | marketscreener.com
Otonomy Sees No Clinically Meaningful Improvement With Higher Doses of OTO-413 in Patients With Hearing Loss - Marketscreener.com
October 13, 2022 | globenewswire.com
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss - GlobeNewswire
October 13, 2022 | finance.yahoo.com
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss - Yahoo Finance
October 13, 2022 | finance.yahoo.com
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss
October 7, 2022 | reuters.com
OTIC.O - Otonomy Inc | Stock Price & Latest News | Reuters
September 27, 2022 | marketscreener.com
APPLIED GENETIC TECHNOLOGIES CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com
September 17, 2022 | marketscreener.com
OTONOMY, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) - Marketscreener.com
See More Headlines


OTIC Company Calendar

Last Earnings
11/10/2021
Today
6/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OTIC
CUSIP
N/A
CIK
1493566
Web
www.otonomy.com
Phone
(619) 323-2200
Fax
619-291-9190
Employees
51
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$0.50
High Stock Price Forecast
$0.50
Low Stock Price Forecast
$0.50
Forecasted Upside/Downside
+5,782.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-51,180,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-137.86%
Return on Assets
-68.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.74
Quick Ratio
1.74

Sales & Book Value

Annual Sales
$130,000.00
Price / Sales
4.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.97 per share
Price / Book
0.01

Miscellaneous

Outstanding Shares
68,527,000
Free Float
67,780,000
Market Cap
$582,479.50
Optionable
Optionable
Beta
1.54

Key Executives

  • Paul E. Cayer
    President, CFO, Secretary & Chief Business Officer
  • Anna Stepannenko
    Vice President -Technical operations
  • Fabrice Piu
    Vice President-Research & Preclinical Development
  • David Skarinsky
    Vice President-Clinical
  • Jeffery J. Anderson
    Vice President-Clinical Sciences

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













OTIC Stock - Frequently Asked Questions

Should I buy or sell Otonomy stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OTIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OTIC, but not buy additional shares or sell existing shares.
View OTIC analyst ratings or view top-rated stocks.

What is Otonomy's stock price forecast for 2023?

2 Wall Street analysts have issued twelve-month price objectives for Otonomy's shares. Their OTIC share price forecasts range from $0.50 to $0.50. On average, they expect the company's share price to reach $0.50 in the next twelve months. This suggests a possible upside of 5,782.4% from the stock's current price.
View analysts price targets for OTIC or view top-rated stocks among Wall Street analysts.

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) issued its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.19). During the same quarter last year, the business earned ($0.22) earnings per share.

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $0.01.

How much money does Otonomy make?

Otonomy (NASDAQ:OTIC) has a market capitalization of $582,479.50 and generates $130,000.00 in revenue each year. The biopharmaceutical company earns $-51,180,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.otonomy.com. The biopharmaceutical company can be reached via phone at (619) 323-2200, via email at ir@otonomy.com, or via fax at 619-291-9190.

This page (NASDAQ:OTIC) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -